跳至主要内容
临床试验/EUCTR2014-005253-39-Outside-EU/EEA
EUCTR2014-005253-39-Outside-EU/EEA进行中(未招募)不适用

A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemophilia A Pediatric Population.

Bayer HealthCare AG0 个研究点目标入组 20 人开始时间: 2015年1月21日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Male - Severe hemophilia A or moderate hemophilia A - 1-12 years of age - Requiring treatment with FVIII
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 20
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Current or prior inhibitor or familial antecedents of inhibitor - Surgery required during the study (9 months) - Positive for HIV

研究者

相似试验

Russian Kogenate Pediatric Study | 临床试验